Anticoagulation in high thromboembolic risk after catheter ablation for atrial fibrillation: Results from the German Ablation Registry

被引:1
|
作者
Moser, J. [1 ]
Kuck, K. H. [2 ]
Andresen, D. [3 ]
Spitzer, S. G. [4 ]
Hoffmann, E. [5 ]
Schumacher, B. [6 ]
Eckardt, L. [7 ]
Brachmann, J. [8 ]
Lewalter, T. [9 ]
Hochadel, M. [10 ]
Senges, J. [10 ]
Willems, S. [1 ]
Hoffmann, B. A. [1 ]
机构
[1] Univ Klinikum Hamburg Eppendorf, Univ Herzzentrum Hamburg, Klin Kardiol Schwerpunkt Elektrophysiol, D-20246 Hamburg, Germany
[2] Asklepios Klin St Georg, Abt Kardiol, Hamburg, Germany
[3] Vivantes Klinikum Urban, Klin Innere Med Kardiol, Berlin, Germany
[4] Praxisklin Herz & Gefasse, Dresden, Germany
[5] Klinikum Bogenhausen, Stadt Kliniken Munchen, Klin Kardiol & Intens Med, Munich, Germany
[6] Westpfalz Klinikum, Med Klin 2, Kaiserslautern, Germany
[7] Univ Klinikum Munster, Abt Rhythmol, Dept Kardiol & Angiol, Munster, Germany
[8] Regiomed Klin, Med Klin 2, Coburg, Germany
[9] Isar Kliniken GmbH, Isar Herz Zentrum, Klin Kardiol & Internist Intens Med, Munich, Germany
[10] Inst Herzinfarktforsch, Ludwigshafen, Germany
关键词
atrial fibrillation; catheter ablation; anticoagulation; guidelines; CHA(2)DS(2)-VASc-Score; ORAL ANTICOAGULATION; FOLLOW-UP; GUIDELINES; MANAGEMENT; INVESTIGATE; CHADS(2); WARFARIN; EVENTS;
D O I
10.1055/s-0034-1387316
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Catheter ablation (CA) for atrial fibrillation (AF) is an effective therapeutic option for the treatment of symptomatic drug-refractory AF. According to current guidelines, the prevention of stroke and embolism is the most important therapeutic goal in AF and the recommendations for anticoagulation (OAC) after successful CA are based upon the CHA(2)DS(2)-VASc-Score [3]. The aim of this study was to evaluate the use of OAC in patients with a high risk for thromboembolic events 1 year after CA and to identify predictor variables for discontinuation of OAC. Methods: Between January 2007 and January 2010 13092 patients were enrolled in the study. A total of 52 German electrophysiological centers agreed to participate in this prospective multicenter registry. 41 centers included patients undergoing CA for AF. Analysis included patients who were discharged with OAC after CA and had a CHA2DS2-VASc-Score >= 2. A centralized 1 year follow-up (FU) was conducted via telephone. Results: 1300 patients fulfilled the inclusion criteria. One year after CA 51.8 % of these patients were on OAC. Factors significantly associated with discontinuation of OAC included no AF recurrence in FU (adjusted odds ratio (OR): 2.14, [95% confidence interval (CI): 1.73-2.66], P < 0.001) and paroxysmal AF (OR: 1.53 [95 % CI: 1.29-1.81], P < 0.001). Factors associated with continuation of OAK were patient age (OR per 10 years: 0.79 [95% CI: 0.68-0.91], P = 0.002), valvular heart disease (OR: 0.67 [95 % CI: 0.48-0.92], P = 0.013), an implanted pacemaker, defibrillator or a cardiac resynchronization therapy system (OR: 0.55 [95 % CI: 0.41-0.74], P < 0.001) and neurological events in hospital or during FU (OR: 0.40 [95 % CI: 0.18-0.88], P < 0.022). Conclusion: Almost half of the patients with an indication for OAC are not adequately anticoagulated one year after CA for AF. Paroxysmal AF or freedom from AF is significantly associated with discontinuation of OAC.
引用
收藏
页码:1923 / 1928
页数:6
相关论文
共 50 条
  • [21] Anticoagulation after Ablation for Atrial Fibrillation
    Kadire, Siri R.
    Al-Khatib, Sana M.
    Calkins, Hugh
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (05): : 466 - 468
  • [22] Incidence of Late Thromboembolic Events After Catheter Ablation of Atrial Fibrillation
    Yagishita, Atsuhiko
    Takahashi, Yoshihide
    Takahashi, Atsushi
    Fujii, Akira
    Kusa, Shigeki
    Fujino, Tadashi
    Nozato, Toshihiro
    Kuwahara, Taishi
    Hirao, Kenzo
    Isobe, Mitsuaki
    CIRCULATION JOURNAL, 2011, 75 (10) : 2343 - 2349
  • [23] Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?
    Romero, Jorge
    Avendano, Ricardo
    Diaz, Juan Carlos
    Taveras, Jose
    Lupercio, Florentino
    Di Biase, Luigi
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (01) : 31 - 41
  • [24] Is it safe to stop oral anticoagulation after catheter ablation of atrial fibrillation?
    Romero, Jorge
    Di Biase, Luigi
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2018, 29 (06) : 833 - 834
  • [25] Spanish catheter ablation registry and atrial fibrillation
    Vazquez Ruiz de Castroviejo, Eduardo
    Lozano Cabezas, Cristobal
    REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (07): : 779 - 779
  • [26] LONG TERM PRESCRIBING OF ANTICOAGULATION AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION
    Arias, Rafael
    Leef, George
    Daimee, Usama
    Calkins, Hugh
    Spragg, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 341 - 341
  • [28] Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry
    Jana Mareike Nührich
    Karl-Heinz Kuck
    Dietrich Andresen
    Daniel Steven
    Stefan G. Spitzer
    Ellen Hoffmann
    Burghard Schumacher
    Lars Eckardt
    Johannes Brachmann
    Thorsten Lewalter
    Matthias Hochadel
    Jochen Senges
    Stephan Willems
    Boris A. Hoffmann
    Clinical Research in Cardiology, 2015, 104 : 463 - 470
  • [29] Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks
    Kanaoka, Koshiro
    Nishida, Taku
    Iwanaga, Yoshitaka
    Nakai, Michikazu
    Tonegawa-Kuji, Reina
    Nishioka, Yuichi
    Myojin, Tomoya
    Okada, Katsuki
    Noda, Tatsuya
    Kusano, Kengo
    Miyamoto, Yoshihiro
    Saito, Yoshihiko
    Imamura, Tomoaki
    EUROPEAN HEART JOURNAL, 2024, 45 (07) : 522 - 534
  • [30] Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry
    Nuehrich, Jana Mareike
    Kuck, Karl-Heinz
    Andresen, Dietrich
    Steven, Daniel
    Spitzer, Stefan G.
    Hoffmann, Ellen
    Schumacher, Burghard
    Eckardt, Lars
    Brachmann, Johannes
    Lewalter, Thorsten
    Hochadel, Matthias
    Senges, Jochen
    Willems, Stephan
    Hoffmann, Boris A.
    CLINICAL RESEARCH IN CARDIOLOGY, 2015, 104 (06) : 463 - 470